Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
复制标题
DOI：
--
复制
发表时间：
2007-05
影响因子：
2.5
通讯作者：
S. Mook;L. V. van’t Veer;E. Rutgers;M. Piccart-Gebhart;F. Cardoso
中科院分区：
文献类型：
--
作者：
S. Mook;L. V. van’t Veer;E. Rutgers;M. Piccart-Gebhart;F. Cardoso
迄今为止，大多数乳腺癌辅助化疗的治疗决定是基于传统的临床病理标准。由于具有相似临床病理特征的乳腺癌肿瘤可能有截然不同的结局，目前对辅助化疗的选择还远远不够准确。使用高通量微阵列分析，确定了70个基因标记，可以准确地选择早期乳腺癌患者，这些患者极有可能发生远处转移，因此可能从辅助化疗中获益最多。本文综述了70基因图谱（Mammaprint）的发展，其回顾性验证和可行性研究，以及其在大型辅助MINDACT （Microarray in node -阴性疾病可能避免化疗）临床试验中的前瞻性验证。
To date, most treatment decisions for adjuvant chemotherapy in breast cancer are sed on conventional clinicopathological criteria. Since breast cancer tumors with similar clinicopathological characteristics can have strikingly different outcomes, the current selection for adjuvant chemotherapy is far from accurate. Using high-throughput microarray analysis, a 70-gene signature was identified which can accurately select early stage breast cancer patients who are highly likely to develop distant metastases, and therefore, may benefit the most from adjuvant chemotherapy. This review describes the development of the 70-gene profile (Mammaprint), its retrospective validation and feasibility studies, and its prospective validation in the large adjuvant MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) clinical trial.